What is the recommended oral dosage of finasteride for benign prostatic hyperplasia and for male pattern hair loss, and what are its contraindications?

Finasteride Dosage

For benign prostatic hyperplasia (BPH), prescribe finasteride 5 mg once daily; for male pattern hair loss (androgenetic alopecia), prescribe finasteride 1 mg once daily. These are the FDA-approved doses with established efficacy for their respective indications 1.

Dosing by Indication

BPH Treatment

• Standard dose: 5 mg once daily orally 1

• This dose produces significant clinical benefits:

  • Reduces acute urinary retention risk 2
  • Decreases need for surgical intervention (TURP, prostatectomy) 1
  • Improves urinary symptoms
  • Reduces prostate volume by approximately 19% 3
  • Increases maximal urinary flow rate by 1.6 mL/second (22% improvement) 3

• Combination therapy: When combined with alpha-blockers (e.g., doxazosin), finasteride 5 mg reduces risk of symptomatic BPH progression 1

• Important clinical note: Prostate volume predicts treatment response—finasteride works best in men with enlarged prostates (>40 mL) 2

Male Pattern Hair Loss

• Standard dose: 1 mg once daily orally 4, 5

• This dose was established through dose-ranging studies showing:

  • 1 mg and 5 mg demonstrated similar efficacy for hair loss 5
  • 1 mg is optimal, balancing efficacy with minimal adverse effects 5
  • Prevents further hair loss in 91% of patients 6
  • Produces visible hair growth in up to 66% of men with mild-moderate alopecia 6

• Lower doses (0.2 mg, 0.01 mg) are inadequate—the 0.01 mg dose showed efficacy similar to placebo 5

Key Contraindications

Absolute contraindications:

• Women of childbearing potential (finasteride is pregnancy category X—causes abnormalities of external genitalia in male fetuses)
• Pregnancy or potential pregnancy
• Hypersensitivity to finasteride or any component

Important warnings:

• Women should not handle crushed or broken tablets if pregnant or potentially pregnant (drug absorbed through skin)
• Not approved for use in women for any indication
• Not approved for prevention of prostate cancer 1

Critical Safety Considerations

Sexual Dysfunction Risk

The most common adverse effects are sexual:

• BPH dose (5 mg): Year 1 rates 1:

  • Impotence: 8.1% (vs 3.7% placebo)
  • Decreased libido: 6.4% (vs 3.4% placebo)
  • Decreased ejaculate volume: 3.7% (vs 0.8% placebo)

• Important pattern: Sexual side effects diminish over time—by years 2-4, rates of impotence and decreased libido were similar between finasteride and placebo groups 1

• Hair loss dose (1 mg): Generally well-tolerated with lower sexual dysfunction rates than 5 mg dose 4, 7

Prostate Cancer Screening Caveat

Finasteride reduces PSA levels by approximately 50%—you must double the PSA value in men taking finasteride to interpret screening results accurately. Any PSA increase while on finasteride warrants investigation for prostate cancer 1.

High-Grade Prostate Cancer Signal

The PCPT trial found higher incidence of Gleason 8-10 prostate cancer in finasteride-treated men (1.8% vs 1.4% placebo), though this remains controversial and may reflect detection bias 1. Finasteride is not approved for prostate cancer prevention 1.

Clinical Pearls

• Onset of action: BPH symptom improvement requires 6-12 months of continuous therapy for maximal benefit
• Duration: Both indications require continuous long-term use—benefits reverse upon discontinuation 6
• Monitoring: Check PSA before starting and periodically during treatment (remember to double the value for interpretation)
• Surgical planning: Inform ophthalmologists before cataract surgery—alpha-blockers (often combined with finasteride for BPH) cause intraoperative floppy iris syndrome 2
• Off-label low-dose use: While 1 mg finasteride shows biologic effects on prostate pathways (PSA suppression), only the 5 mg dose has proven clinical efficacy for BPH outcomes 8